CymaBay Therapeutics, Inc.

CBAY · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$105,370-$106,001-$89,998-$50,986
Dep. & Amort.$681$710$688$632
Deferred Tax-$2,732$0$637$0
Stock-Based Comp.$15,230$9,517$9,996$7,324
Change in WC$5,632-$2,339$6,351-$1,591
Other Non-Cash$14,028$14,033$2,895-$104
Operating Cash Flow-$72,531-$84,080-$69,431-$44,725
Investing Activities
PP&E Inv.-$445-$148-$87-$21
Net Acquisitions-$7,864-$874$637-$104
Inv. Purchases-$305,674-$174,977-$78,084-$176,300
Inv. Sales/Matur.$219,550$129,140$126,760$224,278
Other Inv. Act.$7,864$874-$637$104
Investing Cash Flow-$86,569-$45,985$48,589$47,957
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$345,772$0$70,499$92
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$345,772$24,550$118,455$92
Financing Cash Flow$345,772$24,550$118,455$92
Forex Effect-$428$0$0$0
Net Chg. in Cash$186,244-$105,515$97,613$3,324
Supplemental Information
Beg. Cash$20,291$125,806$28,193$24,869
End Cash$206,535$20,291$125,806$28,193
Free Cash Flow-$72,976-$84,228-$69,518-$44,746